Skip to main content

Table 2 Methods for the detection of immunohistochemical expression of the tested markers

From: Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial

 

Company

Antigen

Blocking

1.AK

2.AK

retrieval

30’RT

AREG

R&D Systems

0,1 M

5% swine

1:75,

LSAB + System-HRP

 

AF262

EDTA buffer pH8

serum

over night

K 0690

EREG

R&D Systems

-

5% swine

1:100

LSAB + System-HRP

 

AF1195

 

serum

over night

K 0690

VEGF-C

Sant Cruz

-

FFP

1:50

Dako Realâ„¢EnVisionâ„¢Detection System

 

sc-9047

  

over night

K 5007

VEGF-D

Sant Cruz

0.01 M

FFP

1:50

Dako Realâ„¢EnVisionâ„¢Detection System

 

sc-13085

Citrat buffer

 

2 h RT

K 5007

VEGFR-3

Sant Cruz

0.01 M

FFP

1:100

LSAB + System-HRP

 

sc-321

Citrat buffer

 

2 h RT

K 0690

Hif-1 α

Sant Cruz

0,1 M

5% swine

1:50

LSAB + System-HRP

 

sc-53546

EDTA buffer pH8

serum

over night

K 0690

PTEN

Cell Signaling

0.01 M

5% goat

1:75

Dako Realâ„¢EnVisionâ„¢Detection System

 

9188’s

Citrat buffer

serum

over night

K 5007

  1. RT room temperature, FFP fresh frozen plasma.